September 23, 2021 – Corticosteroid injections are a common treatment option for pain and inflammation in patients with osteoarthritis of the hip. But a new study adds to concerns that hip steroid injections may lead to increased rates of a serious complication called rapidly destructive hip disease (RDHD), according to a paper in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
The increased rates of RDHD are especially apparent in patients receiving repeated and/or high-dose corticosteroid hip injections, according to the report by Kanu Okike, MD, MPH, of Hawaii Permanente Medical Group, Honolulu, and colleagues. Their study includes the largest series of patients with post-injection RDHD reported to date.
New evidence of increased RHDH risk following corticosteroid injection
Dr. Okike and colleagues used two different research approaches to assess the possible association between intra-articular (i.e., inside the joint) corticosteroid injection and RDHD. The first part of the study compared 40 hips that developed RDHD and 717 hips that underwent total hip arthroplasty for other reasons between 2013 and 2016.
After adjusting for other factors, “[H]ip corticosteroid injections were found to increase the likelihood of RDHD approximately 8.5-fold,” according to the authors. The analysis also showed evidence of a “dose-response” effect: the likelihood of RDHD was about 5 times greater in patients who received low-dose corticosteroid injections and nearly 10 times greater with high-dose injections. “A similar dose-response pattern was observed for the number of injections performed,” Dr. Okike and coauthors add.
In the second part of the study, the researchers reviewed data on 688 hips that underwent corticosteroid injection during the same period. Thirty-seven of these hips developed post-injection RDHD, for an incidence of 5.4 percent. The diagnosis of RDHD was made an average of five months after injection; all patients underwent THA.
As in the first part of the study, the risk of post-injection RDHD was higher in hips that received a higher dose of corticosteroids and a greater number of injections. The authors suggest that the risk of RDHD following a single, low-dose injection is relatively low: about two percent. However, risk may increase to five percent following multiple low-dose injections or a single high-dose injection, and up to 10 percent following multiple high-dose injections.
As they became aware of the possible link with RDHD, orthopaedic surgeons at the study hospital started ordering fewer hip corticosteroid injections and avoiding high-dose injections. In subsequent years, the number of RDHD cases decreased, even as the number of THAs performed for other reasons remained stable.
“[T]he present study provides evidence of an association between RDHD and intra-articular hip corticosteroid injection,” Dr. Okike and colleagues conclude. They add that while the evidence suggests that hip corticosteroid injections lead to an increased risk of RDHD, the study cannot confirm a true causal effect.
The researchers believe their findings can help to guide clinical practice for patients with painful hip osteoarthritis. Dr. Okike and colleagues note that their department has added a discussion of post-injection RDHD to the informed consent process for patients considering hip corticosteroid injection and has stopped performing high-dose corticosteroid injections.
DOI: 10.2106/JBJS.20.02155
###
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
